Sintilimab, an IgG4 monoclonal antibody, mitigates tumor-induced immunosuppression by binding to programmed cell death protein 1 (PD-1), inhibiting its interaction with programmed death ligands2. The gene discussed is PDCD1; the disease is neoplasm.